|
|
Blood, 1 July 2008, Vol. 112, No. 1, pp. 210.
Previous Article | Table of Contents
CORRESPONDENCE
Response: Natalizumab-induced mobilization of CD34+ hematopoietic progenitor cells
We thank Vuaillat et al for reading our paper1 carefully with great interest.
Within this short correspondence we hope to elucidate the questions raised: - All 5 untreated patients met both the McDonald and the Barkhoff criteria and were diagnosed between 2002 and 2006 with the relapsing-remitting form of the disease. Therefore they had experienced more than one relapse episode of the disease.
- The patients had the following blood-circulating CD34+ counts: 0.57/µL; 0.8/µL; 1.06/µL; 1.44/µL and 1.68/µL.
- For CD34+ subset analysis we performed dual-color phenotyping, and all circulating CD34+ cells belonged to the subset of more committed progenitors coexpressing CD38.
 |
Authorship
|
|---|
Conflict-of-interest disclosure: The author declares no competing financial interests.
Correspondence: Fabian Zohren, Heinrich Heine University, Moorenstr 5, Duesseldorf, Germany 40225; e-mail: fabian.zohren{at}med.uni-duesseldorf.de.
Fabian Zohren
 |
Reference
|
|---|
- Zohren F, Toutzaris D, Klärner V, Hartung H-P, Kieseier B, Haas R. The monoclonal anti–VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood. 2008;111:3893–3895.[Abstract/Free Full Text]

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Articles in Blood Online:
-
About multiple sclerosis, natalizumab, and CD34+ hematopoietic progenitors
- Carine Vuaillat, Géraldine Androdias, Nathalie Davoust, and Serge Nataf
Blood 2008 112: 208-209.
[Full Text]
[PDF]
-
The monoclonal anti–VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans
- Fabian Zohren, Diamandis Toutzaris, Viola Klärner, Hans-Peter Hartung, Bernd Kieseier, and Rainer Haas
Blood 2008 111: 3893-3895.
[Abstract]
[Full Text]
[PDF]
|
|